公开(公告)号：US20250017914A1

公开(公告)日：2025-01-16

申请号：US18689967

申请日：2022-09-09

Applicant: Black Diamond Therapeutics, Inc.

Inventor： Pui Yee NG ,  Ivan JEWETT ,  Fernando PADILLA

IPC: A61K31/444 ,  A61K31/4375 ,  A61K31/501 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.

公开(公告)号：US20250017856A1

公开(公告)日：2025-01-16

申请号：US18773063

申请日：2024-07-15

Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Inventor： Kai Vincent Slaughter ,  Molly Sandra Shoichet ,  Eric Niel Rummens Donders

IPC: A61K9/127 ,  A61K9/51 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/565 ,  A61K31/7088 ,  A61K45/06

Abstract: A co-formulation comprising: (i) an ionizable colloid forming active substance; (ii) a nucleic acid molecule; and (iii) an amphiphilic molecule. Also, a method of treating a disease or disorder comprising administering the co-formulation to a subject in need, wherein the ionizable colloid-forming active substance and the nucleic acid molecule included in the co-formulation act together in the treatment of the disease or disorder; and a method of manufacturing the co-formulation.

公开(公告)号：US12186413B2

公开(公告)日：2025-01-07

申请号：US17441611

申请日：2020-03-27

Applicant: KOWA COMPANY, LTD.

Inventor： Misako Nakashima ,  Koichiro Iohara

IPC: A61K6/54 ,  A61K6/69 ,  A61K6/80 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/4725 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K45/06 ,  A61L27/22 ,  A61L27/36 ,  A61L27/54 ,  A61P1/02

Abstract: A non-cellular root canal filler comprises a tetrahydroisoquinoline compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt, and a dental tissue regeneration promotion kit comprises a pretreatment agent comprising a serine protease, and the non-cellular root canal filler.

公开(公告)号：US20250000870A1

公开(公告)日：2025-01-02

申请号：US18708204

申请日：2022-11-07

Applicant: Cellestia Biotech AG

Inventor： Rajwinder Lehal ,  Charlotte Urech ,  Sebastein Lamy

IPC: A61K31/5377 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/506 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to pharmaceutical combinations comprising a kinase inhibitor and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.

公开(公告)号：US12178798B2

公开(公告)日：2024-12-31

申请号：US17533296

申请日：2021-11-23

Applicant: INSECTERGY, LLC

Inventor： Daniel Michael Leo

IPC: A61K31/352 ,  A23G1/36 ,  A23G1/40 ,  A23G1/48 ,  A23G3/36 ,  A23G3/40 ,  A23G3/42 ,  A23G3/48 ,  A23G3/54 ,  A61K9/00 ,  A61K31/05 ,  A61K31/36 ,  A61K31/4045 ,  A61K31/4375 ,  A61K31/675 ,  A61K36/185 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/46

Abstract: Insects are grown then harvested, mixed with ingredients, and then used to produce products. Insect are grown within an interior of an enclosure and heat is removed therefrom by providing a refrigerant vapor, condensing the refrigerant vapor to produce a liquid refrigerant, and evaporating the liquid refrigerant by transferring the heat from the interior of the enclosure to the liquid refrigerant. Insects eat feedstock and excrete insect frass which is then collected for use as a fertilizer. Also described is insect breeding and insect lipid extraction. Cannabis plants may be grown together with the insects.

公开(公告)号：US20240415818A1

公开(公告)日：2024-12-19

申请号：US18631891

申请日：2024-04-10

Applicant: Deciphera Pharmaceuticals, LLC

Inventor： Daniel L. Flynn ,  Bryan D. Smith ,  Anu Gupta

IPC: A61K31/4375 ,  A61K45/06 ,  A61P35/04

Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

公开(公告)号：US12168022B2

公开(公告)日：2024-12-17

申请号：US17962115

申请日：2022-10-07

Applicant: INSMED INCORPORATED

Inventor： Gina Eagle ,  Renu Gupta

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20240400577A1

公开(公告)日：2024-12-05

申请号：US18577481

申请日：2022-07-07

Applicant: VIBLIOME THERAPEUTICS, LLC

Inventor： Gary A. Flynn ,  Paul Galatsis ,  Andrew C. Huntsman ,  Khoi Huynh ,  Doug Werner

IPC: C07D495/04 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/52 ,  A61K31/5377 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04

Abstract: Provided herein are small molecule protein kinase modulators, pharmaceutical compositions comprising such, and their uses in treating one or more conditions.

公开(公告)号：US20240390345A1

公开(公告)日：2024-11-28

申请号：US18795731

申请日：2024-08-06

Applicant: Deciphera Pharmaceuticals, LLC

Inventor： Michael D. Kaufman ,  Scott Bone ,  Corey Bloom ,  Fred Jordan

IPC: A61K31/4375 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

公开(公告)号：US20240390335A1

公开(公告)日：2024-11-28

申请号：US18691158

申请日：2021-11-09

Applicant: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES ,  GUANGZHOU HC NEW DRUG RESEARCH CO., LTD.

Inventor： Danqing SONG ,  Jiandong JIANG ,  Yanxiang WANG ,  Xuefu YOU ,  Shengxi FENG ,  Yinghong LI ,  Xi LU ,  Lidong LIN ,  Tianyun FAN ,  Jing PANG ,  Zhihao GUO ,  Zhiwen LI ,  Yonghua LIU ,  Xiukun WANG

IPC: A61K31/427 ,  A61K31/167 ,  A61K31/4375 ,  A61K31/551 ,  A61K31/58 ,  A61K31/69 ,  A61P31/04

Abstract: The present invention relates to a pharmaceutical composition comprising a β-lactam compound of formula (I), or a stereoisomer, a solvate or a pharmaceutically acceptable salt or ester thereof, and a lactamase inhibitor or an efflux pump inhibitor, and the use thereof for inhibiting microorganisms, particularly bacteria, especially Gram-negative bacteria, wherein each symbol in formula (I) is as defined in the description.